Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Hum Pathol. 2010 May;41(5):663-71. doi: 10.1016/j.humpath.2009.10.005. Epub 2009 Dec 11.
In this article, we supplement the few published articles by describing the clinical and pathologic features of pleomorphic and dedifferentiated leiomyosarcoma from 41 patients (27 women and 14 men) with an age range of 25 to 75 years (mean, 56.5 years), representing the largest cohort reported to date. The typical leiomyosarcoma component accounted for <5% to 60% (mean, 15%) of the tumor. The pleomorphic sarcoma component was composed of polygonal cells in 57% of cases, spindle cells in 21%, a combination of polygonal, epithelioid, rhabdoid, and/or spindle cells in 18%, and predominantly epithelioid cells in 3%. The classical leiomyosarcoma component was positive for at least one myogenic immunohistochemical marker in 29 tumors tested; smooth muscle actin in 100% (27/27), calponin in 90% (9/10), muscle-specific actin in 90% (10/11), desmin in 86% (23/27), smooth muscle myosin heavy chain (SMMS-1) in 67% (4/6), and caldesmon in 57% (4/7). The pleomorphic sarcoma component was reactive for at least one muscle marker in 77% (23/30) of cases; smooth muscle actin in 63% (17/27), calponin in 60% (6/10), SMMS-1 in 60% (3/5), desmin in 59% (16/27), muscle-specific actin in 40% (4/10), and caldesmon in 29% (2/7). The classical leiomyosarcoma component was often strongly positive for myogenic markers, and the pleomorphic sarcoma component usually showed focal and less intense immunoreactivity. Based on staining for muscle markers in the pleomorphic component, twenty-three cases were designated as pleomorphic leiomyosarcoma, and 7 cases were designated as dedifferentiated leiomyosarcoma (negative for all muscle markers used). Eleven cases, in which tissue was not available for immunhistochemical stains, the question of pleomorphic versus dedifferentiated leiomyosarcoma could not be answered. The incidence of metastasis was 89% (32/36) and the mortality rate was 50% (18/36) at last follow-up (3-104 months; mean, 27.5 months).
本文补充了少数已发表的文章,描述了 41 例(27 名女性和 14 名男性)具有多形性和去分化特征的平滑肌肉瘤的临床和病理特征,年龄 25 至 75 岁(平均年龄 56.5 岁),这是迄今为止报告的最大队列。典型的平滑肌肉瘤成分占肿瘤的<5%至 60%(平均 15%)。多形性肉瘤成分由 57%的多边形细胞组成,21%的梭形细胞组成,18%的多边形、上皮样、横纹肌样和/或梭形细胞的组合组成,3%的主要由上皮样细胞组成。在 29 例接受检测的肿瘤中,至少有 1 种肌源性免疫组织化学标志物阳性,在 100%(27/27)的病例中平滑肌肌动蛋白阳性,在 90%(9/10)的病例中钙调蛋白阳性,在 90%(11/11)的病例中肌特异性肌动蛋白阳性,在 86%(23/27)的病例中结蛋白阳性,在 67%(4/6)的病例中平滑肌肌球蛋白重链(SMMS-1)阳性,在 57%(4/7)的病例中钙调蛋白阳性。在 77%(23/30)的病例中,多形性肉瘤成分至少对 1 种肌标记物呈阳性反应;在 63%(17/27)的病例中平滑肌肌动蛋白阳性,在 60%(6/10)的病例中钙调蛋白阳性,在 60%(3/5)的病例中 SMMS-1 阳性,在 59%(16/27)的病例中结蛋白阳性,在 40%(4/10)的病例中肌特异性肌动蛋白阳性,在 29%(2/7)的病例中钙调蛋白阳性。典型的平滑肌肉瘤成分通常对肌源性标志物呈强阳性反应,而多形性肉瘤成分通常呈局灶性和较弱的免疫反应性。根据多形性成分中肌肉标志物的染色,23 例被诊断为多形性平滑肌肉瘤,7 例被诊断为去分化平滑肌肉瘤(所有使用的肌肉标志物均为阴性)。11 例未进行免疫组织化学染色的病例,无法确定多形性与去分化平滑肌肉瘤的问题。转移的发生率为 89%(32/36),截至最后随访(3-104 个月;平均 27.5 个月)的死亡率为 50%(18/36)。